Continued Cuts to Reimbursement Prices
First written in FY2016. 16 of 33 entries say "Materialised", first in FY2020-Q3. Latest entry: 2026-07-30.
Japan Lifeline moved to the "Worse" side of this theme in 2020, 2 years after the typical company in this theme (2018).
The whole theme swung hardest in 2020: 4 of 12 companies on the "Worse" side.
1 other company's latest entry also says "Mitigated".
- FY2026-H1MitigatedAnnual report
「The June 2024 reimbursement price revision resulted in a two-month year-on-year impact from lower selling prices, but this was offset by higher sales volumes in the core and growth businesses.」
Although selling prices declined due to the reimbursement price revision, the impact during the current interim period was offset by higher sales volumes in the core and growth businesses. - FY2025MaterialisedAnnual report
「The revision implemented in June 2024 had a negative impact of approximately 2% on consolidated sales for the fiscal year ending March 2025 compared with the previous fiscal year.」
Continuing reductions in reimbursement prices actually occurred and had an approximately 2% negative impact on consolidated sales for the current fiscal year. - FY2025-H1MaterialisedAnnual report
「Although reimbursement price revisions caused selling prices to decline, the resulting impact was offset by higher sales volumes as the EP/ablation and cardiovascular-related markets expanded.」
The decline in selling prices resulting from the June 2024 reimbursement price revision actually occurred, but its impact was offset by higher sales volumes. - FY2024-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there had been no material changes regarding the continuing risk of reimbursement price reductions. - FY2023RestatedAnnual report
「The revision implemented in April 2022 had an impact equivalent to approximately 4% of consolidated sales for the fiscal year ending March 2023. To prepare for the risk of unexpected reductions in reimbursement prices, the company will continuously monitor trends in the medical insurance system and reimbursement price revisions, while seeking to reduce risk by introducing highly novel products that are less susceptible to the impact of reimbursement price revisions.」
The company reiterated the approximately 4% impact of the April 2022 revision on annual sales and the mitigation measure of introducing highly novel products. - FY2023-Q3MaterialisedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, selling prices declined for many products year on year as a result of the reimbursement price revision in April 2022. In particular, reimbursement prices were reduced significantly for certain rhythm device and EP/ablation products, exerting a negative impact on sales and gross profit.」
The decline in selling prices resulting from the April 2022 reimbursement price revision and its negative impact on sales and gross profit continued through the cumulative third quarter. - FY2023-Q2MaterialisedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, selling prices declined for many products year on year as a result of the reimbursement price revision in April 2022. In particular, reimbursement prices were reduced significantly for certain rhythm device and EP/ablation products, exerting a negative impact on sales and gross profit.」
The April 2022 reimbursement price revision caused selling prices to decline for many products, and a negative impact on sales and gross profit materialized through the cumulative second quarter. - FY2023-Q1MaterialisedAnnual report
「During the cumulative first quarter of the current consolidated fiscal year, selling prices declined for many products year on year as a result of the reimbursement price revision in April 2022. In particular, reimbursement prices were reduced significantly for certain rhythm device and EP/ablation products, exerting a certain negative impact on sales and gross profit margin.」
The April 2022 reimbursement price revision caused selling prices to decline for many products, and had an actual negative impact on sales and gross profit margin. - FY2022MaterialisedAnnual report
「The revision implemented in April 2022 had an impact equivalent to approximately 4% of annual consolidated sales.」
The reduction in reimbursement prices materialized, and the impact of the April 2022 revision on annual consolidated sales was quantified at approximately 4%. The company cited the introduction of highly novel products as a measure to reduce risk. - FY2022-Q3MaterialisedAnnual report
「The company's one-of-a-kind S-ICD product, EMBLEM MRI S-ICD, and CRT-Ds were affected by competing products, while the phased reimbursement price reductions for S-ICD leads in January and April 2021 also contributed to a slight year-on-year decline in sales of ICD-related products.」
The phased reimbursement price reductions in January and April 2021 had an actual impact on sales of S-ICD leads and, together with the impact of competing products, contributed to a slight decline in ICD-related sales. - FY2022-Q2MaterialisedAnnual report
「In the ICD-related business, the company's one-of-a-kind S-ICD product, EMBLEM MRI S-ICD, and CRT-Ds (biventricular pacemakers with defibrillation) featuring proprietary patient-monitoring functions performed steadily. However, S-ICD leads were affected by the phased reimbursement price reductions in January and April 2021, while sales of conventional ICDs (implantable cardioverter-defibrillators) also declined year on year due in part to postponed scheduled procedures.」
The phased reimbursement price reductions in January and April 2021 had an actual impact on sales of S-ICD leads, while sales of conventional ICDs also declined amid postponed scheduled procedures. - FY2022-Q1MaterialisedAnnual report
「In the ICD-related business for the treatment of tachycardia, the company's one-of-a-kind S-ICD product, EMBLEM MRI S-ICD, performed steadily. However, S-ICD leads were affected by the phased reimbursement price reductions in January and April 2021, while sales of conventional ICDs (implantable cardioverter-defibrillators) and CRT-Ds (biventricular pacemakers with defibrillation) declined year on year, partly due to the impact of competing products.」
The phased reimbursement price reductions in January and April 2021 had an actual impact on sales of S-ICD leads. - FY2021MaterialisedAnnual report
「The revision implemented in April 2020 had an impact equivalent to approximately 2–3% of annual consolidated sales.」
The impact of lower reimbursement prices materialized, and the impact of the April 2020 revision on annual consolidated sales was quantified at approximately 2–3%. - FY2021-Q3MaterialisedAnnual report
「In addition, the April 2020 revision had a financial impact, as prices were reduced across all medical devices handled by the company.」
The across-the-board price reductions resulting from the April 2020 reimbursement price revision had an actual impact on sales of products such as EP/ablation and intervention devices. - FY2021-Q2MaterialisedAnnual report
「In addition, the revisions to reimbursement prices in October 2019 and April 2020 had a financial impact, as prices were reduced across all medical devices handled by the company.」
The across-the-board price reductions resulting from the October 2019 and April 2020 reimbursement price revisions had an actual impact on sales in the cumulative second quarter. - FY2021-Q1MaterialisedAnnual report
「The reimbursement price revisions in October 2019 and April 2020 also had a monetary impact because prices were reduced across the medical devices we handle.」
The broad price reductions resulting from the reimbursement price revisions in October 2019 and April 2020 had an actual impact on revenue in the first quarter. - FY2020MaterialisedAnnual report
「Regarding the impact of past reimbursement price revisions, we recognize that the revision implemented in April 2018 had an impact of approximately 6% of consolidated revenue for the fiscal year, while the revision implemented in October 2019 had an impact of approximately 3% of consolidated revenue for the second half of the fiscal year ending March 2020.」
The impact of reimbursement price reductions was quantified by revision, with the October 2019 revision described as having an impact of approximately 3% on revenue for the second half of the current fiscal year. - FY2020-Q3MaterialisedAnnual report
「In addition to the low contribution to profit from S-ICD during its prelaunch sales period, the revision of reimbursement prices in October 2019 accompanying the consumption tax increase also affected gross profit margin, which declined by 4.8 percentage points from the year-earlier period.」
The impact of the reimbursement price revision associated with the consumption tax increase materialized, and gross profit margin declined by 4.8 percentage points, together with the low profit contribution from S-ICD during its prelaunch sales period. - FY2020-Q2RestatedAnnual report
「No new business or other risks arose during the six-month period ended [the second quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It has been disclosed that there has been no material change in the risk of continued reductions in reimbursement prices. - FY2020-Q1RestatedAnnual report
「No new business or other risks arose during the three-month period ended [the first quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It has been disclosed that there has been no material change in the risk of continued reductions in reimbursement prices. - FY2019RestatedAnnual report
「As part of measures to contain medical costs, reimbursement prices for specified insurance medical materials continue to be reviewed.」
The continued reduction of reimbursement prices has been reiterated as a major risk, along with mitigation measures such as expanding the product lineup and setting transaction terms. - FY2019-Q3RestatedAnnual report
「During the cumulative third-quarter consolidated accounting period, sales were affected by the revision of official reimbursement prices for medical devices implemented in April 2018. In addition, sales of existing rhythm device products declined following the announcement of a change in supplier. However, revenue from other product categories increased from the year-earlier period due to contributions from our own products and newly added products.」
Although the impact of the April 2018 reimbursement price revision continued during the current quarter, overall revenue increased due to contributions from our own products and new products in other categories. - FY2019-Q2RestatedAnnual report
「In terms of sales performance for the six months ended 30 September, although the revision of reimbursement prices for medical devices in April, which lowered prices across our product portfolio, had an impact, higher sales volumes of existing products supported by an increase in procedures and contributions from newly introduced products offset the impact of the price reductions, resulting in higher sales.」
Although prices were reduced across our product portfolio during the current quarter, the impact was absorbed through higher volumes of existing products and contributions from new products, resulting in higher revenue. - FY2019-Q1MitigatedAnnual report
「Although the April revision of reimbursement prices lowered prices across our product portfolio, higher sales volumes of existing products and the introduction of new products offset the impact of the price reductions, resulting in higher sales.」
Although reimbursement prices were reduced during the current quarter, the impact was absorbed through higher volumes of existing products and the introduction of new products, resulting in higher revenue. - FY2018RestatedAnnual report
「As part of measures to contain medical costs, reimbursement prices for specified insurance medical materials are generally reviewed every 2 years in conjunction with revisions to medical-service fees. Most of the reimbursement prices for the products we handle were subject to reductions in the latest comprehensive price revision, conducted in April this year. If reimbursement prices continue to be reduced, selling prices for products may decline, potentially affecting the operating results and financial position of our Group.」
The structure of revisions generally occurring every 2 years and most products being subject to reductions continues to be described as a risk. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The risk of continued reductions in reimbursement prices is treated as having no material change. No new specific description of the impact of price revisions has been added. - FY2017MitigatedAnnual report
「In terms of profit, despite the revision of reimbursement prices, the gross profit margin improved 2.7 percentage points from the previous fiscal year due to lower costs for our own products and a higher sales mix of highly profitable new sourced products.」
Although reimbursement prices were revised, the impact on profitability was absorbed through cost improvements and a higher proportion of high-margin products. - FY2017-Q3MitigatedAnnual report
「Although the revision of official reimbursement prices for medical devices implemented in April last year reduced prices for most of the products we handle, the impact on performance was limited compared with previous revisions. This was due to the smaller reductions for one-of-a-kind products and other products that make a significant contribution to our performance, as well as the shift of major products we handle to new products in functional categories with higher reimbursement prices.」
Although prices were reduced for most products, the impact on performance was considered limited due to the shift to one-of-a-kind products and new products with higher reimbursement prices. - FY2017-Q2MitigatedAnnual report
「Although prices were reduced for most of the products we handle, the impact on performance was limited compared with previous price revisions because price reductions for one-of-a-kind products and other products with a high contribution to performance were smaller, and our key products have shifted to new products in functional categories with high reimbursement prices.」
Although the price revision resulted in reductions, the impact was more limited than previously due to the smaller reductions for one-of-a-kind products and the shift to new products with higher reimbursement prices. - FY2017-Q1MitigatedAnnual report
「Although the April revision of official reimbursement prices for medical devices reduced prices for most of the products we handle, the impact of the revision was more limited than previously because the reduction was smaller for one-of-a-kind products that make a significant contribution to our performance, among other factors.」
Although reimbursement prices were reduced, the reduction was smaller for one-of-a-kind products, and the impact on performance was more limited than previously. - FY2016First statedAnnual report
「Reimbursement prices for specified insurance medical materials are generally reviewed every 2 years in conjunction with revisions to medical-service fees. Most of the reimbursement prices for the products we handle were subject to reductions in the latest comprehensive price revision, conducted in April this year.」
The disclosure describes the usual price revisions every 2 years and the reductions applied to most products during the current year. Further reductions going forward are identified as a risk.